July 2, 2021

Lisa Ricciardi Chief Executive Officer COGNITION THERAPEUTICS INC 2403 Sidney Street Pittsburgh, Pennsylvania 15203

Re: COGNITION

THERAPEUTICS INC

Amendment No. 1 to

Draft Registration Statement on Form S-1

Submitted June 23,

2021

CIK No. 0001455365

Dear Ms. Ricciardi:

We have reviewed your amended draft registration statement and have the following

comments. In some of our comments, we may ask you to provide us with information so we

may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting

an amended draft registration statement or publicly filing your registration statement on $% \left(1\right) =\left(1\right) +\left(1\right) +$

 $\ensuremath{\mathsf{EDGAR}}.$ If you do not believe our comments apply to your facts and circumstances or do not

believe an amendment is appropriate, please tell us why in your response.

 $\qquad \qquad \text{After reviewing the information you provide in response to these comments and your } \\$

amended draft registration statement or filed registration statement, we may have additional $\ensuremath{\mathsf{A}}$

comments.

Amendment No. 1 to Draft Registration Statement, Submitted June 23, 2021 Summary, page 1

1. We note your response to our prior comment number 3. Please revise your disclosure and the pipeline table and disclosure to name the last two candidates in the pipeline table or remove them from the

pipeline table.

Lisa Ricciardi

FirstName LastNameLisa Ricciardi COGNITION THERAPEUTICS INC

Comapany

July 2, 2021NameCOGNITION THERAPEUTICS INC

July 2,2 2021 Page 2

Page

FirstName LastName

Management's Discussion and Analysis of Financial Condition and Results Of Operations

Contractual Obligations, page 88

2. We note that you have not included your Simple Agreements for Future Equity or $\ensuremath{\mathsf{Simple}}$

convertible notes in your contractual obligations table as of March 31, 2021. Please

explain to us why these obligations were not included in your table or revise your

disclosure to include these obligations.

You may contact Eric Atallah at 202-551-3663 or Kevin Kuhar at 202-551-3662 if you

have questions regarding comments on the financial statements and related matters. Please $\,$

contact Margaret Schwartz at 202-551-7153 or Celeste Murphy at 202-551-3257 with any other

questions.

Corporation Finance

Division of

Sincerely,

Office of Life

Sciences

cc: Rachael M. Bushey, Esq.